CSIMarket
 
Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
 
 


The ascending company from the Major Pharmaceutical Preparations sector the Frequency Therapeutics Inc published the financial third quarter of 2022, results

company recorded third quarter of 2022 operating loss of $-20.275 millions

Published 2022-11-10T15:28:55+00:00
Goran Soko / CSIMarket.com Contributer

pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons The investors have not assumed any adjustments at the business throughout the the July to September 30 2022 reporting season at the FREQ. Yet, they consider the company's operating loss that came in at $-20.275 millions, during the matching time.

Now, it's apparent that, the evolving company managed to work more economically, then in the corresponding span a year before. Ascending from operating loss of $-24.99 millions.


During the third quarter of 2022 earnings season, the management has operated the FREQ much more economically and sliced the deficit to $-19.547 millions.


Frequency Therapeutics Inc is expected to report next financial recent numbers on March 14, 2023.


    Recently Reported Results
161026-G-MI999-007o__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Common Borrowmoney Com Inc

The company announced Revenue of $3.4694469519536e-18 millions, in the most recent fiscal period

Borrowmoney Com Inc proclaimed $3.4694469519536e-18 millions, in Revenue in the fourth quarter of 2022 earnings season.

By_Marcela_pd_via_Wikimedia_Commons Consumer Price Index

Consumer prices increased in October 2022


glowing-2245832__340 Arrowhead Pharmaceuticals Inc

Shortfall on Weak Sales the company during the fourth quarter of 2022 earnings season

For the financial time-frame ending September 30 2022 Arrowhead Pharmaceuticals Inc increased a loss per share of $-0.81 per share compare to $-0.61 a year ago and surged loss from $-0.68 per share from the previous reporting period.

Revenues declined in double digits by -17.52 % to $31.58 millions from $38.28 millions in the comparable reporting period a year ago and sequentially Revenue decreased by -2.582 % from $32.41 millions.

Inflation rate, consumer prices by category

Consumer prices by category monthly change

closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons Anavex Life Sciences Corp

Top-line and bottom-line have crumbled at in the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season AVXL EPS dived by -66.46 % of $0.09 per share compare to $0.26 a year ago and from $0.00 per share from the preceding financial reporting period.

Revenues faded by -43.05 % to $2.20 millions from $3.86 millions in the similar financial reporting period a year ago and sequentially Revenue doubled by 1122.234 % from $0.18 millions.

Inflation rate, consumer prices by category

Consumer prices by category monthly change

pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons Lexaria Bioscience Corp

An extraordinary conduct by Lexaria Bioscience Corp in the financial span ending August 31 2022

Lexaria Bioscience Corp announced very solid Revenue rise of 289.467 % year on year to $0.11 millions in the financial span ending August 31 2022, but increased a deficit per share at $-0.25.

Inflation rate, consumer prices by category

Consumer prices by category monthly change

unemployed_lines_pd Employment Report

Economy gains 315,000 jobs, but the unemployment rate climbs to 3.7 %

The nonfarm payrolls grew 315,000 in August, as faster hiring puts more money in the hands of consumers, what usually leads to an increase in spending,

turn-on-2932999__340